Introduction
============

Tumors of the spinal cord and cauda equina have a wide spectrum of histology and require care with diagnosis and surgical intervention. The differential diagnosis for intradural spinal tumors includes meningioma, nerve sheath tumors such as schwannoma or neurofibroma, astrocytoma, ependymoma, and metastasis. Spinal cord and cauda equina tumors are uncommon neoplasms, and the majority is extramedullary tumors ([@b1-ol-0-0-11786]). Spinal involvement of extraskeletal Ewing sarcoma in the epidural space or paravertebral area is also a differential disease ([@b2-ol-0-0-11786]). Ewing sarcoma is an aggressive bone and soft tissue tumor that usually affects adolescents and young adults ([@b3-ol-0-0-11786],[@b4-ol-0-0-11786]). The Ewing sarcoma family of tumors are a group of high-grade small round cell tumors, including primitive neuroectodermal tumor (pPNET) and Askin tumor. Extraskeletal Ewing sarcoma is more likely to arise in axial locations, compared to Ewing sarcoma of bone ([@b5-ol-0-0-11786]). Most cases of Ewing sarcoma occur in the long bones, pelvis, or ribs, and rarely in extraskeletal regions such as the paravertebral or epidural space, whereas a primary intradural extramedurally Ewing sarcoma (IEES) is extremely rare. In general, Ewing sarcoma is treated with a multimodal approach including surgery and/or focal radiotherapy, in addition to systematic chemotherapy ([@b4-ol-0-0-11786]). However, because of its rarity and limited evidence regarding the therapeutic aspects of IEES, there are no standard treatment guidelines for these tumors even though the aggressive malignant tumor causes severe neurologic morbidity and mortality without appropriate treatment. In addition, the initial imaging and clinical findings of IEES mimic those for benign intradural spinal tumors. Therefore, it is important for oncologists and neurosurgeons to be familiar with the clinical presentation and evaluation of IEES. Here, we describe a case of IEES with meningeal seeding, and we present a literature review of the management and clinical course of this type of tumor.

Case report
===========

A previously healthy 35-year-old woman developed severe lumbago and radicular leg pain on both sides. The symptoms gradually worsened for 2 months after appearance and paresthesia of both legs progressed. Neurologically, straight leg raising and femoral nerve stretch tests were negative on both sides. There was hypoesthesia in the right-side dominant L5-S1 dermatomes. Patellar tendon and Achilles tendon reflexes were normal and Babinski and Chaddock reflexes were negative on both sides. The manual muscle test score was 3 in the right gastrocnemius muscle. Bladder and bowel functions were normal.

Magnetic resonance imaging (MRI) at a previous hospital showed tumorous lesions at the T12-L1 and L4-5 levels ([Fig. 1](#f1-ol-0-0-11786){ref-type="fig"}). The lesion at L4-5 was oval with an isointense signal on T1-weighted images and low-signal intensity on T2-weighted images. The lesion at T12-L1 was semi-oval with an isointense signal on T1-weighted images and low- to high-signal inhomogeneous intensity on T2-weighted images. Surgical treatment was planned based on suspicion of benign multiple schwannoma and ependymoma, but MRI taken 3 weeks after the first visit showed growth and an increased number of intradural tumors. Gadolinium-contrast T1-weighted images showed diffuse enhancement in the tumorous lesions ([Fig. 1](#f1-ol-0-0-11786){ref-type="fig"}).

The rapid changes on MRI led us to strongly suspect a malignant tumor, and we performed a whole-body imaging test. MRI of the cervical and thoracic spinal cord showed enhanced skip lesions on contrast-enhanced T1-weighted images, but brain MRI showed no brain metastases. Computed tomography (CT) of the chest, abdomen and pelvis, and whole-body positron emission tomography (PET) showed no disease ([Fig. 2](#f2-ol-0-0-11786){ref-type="fig"}). From these findings, a malignant tumor was suspected, including metastases of meningeal dissemination, malignant peripheral nerve sheath tumor, malignant lymphoma, and anaplastic ependymoma (WHO grade 3).

The tumor occupied the entire space within the dural tube at the T12-L1 level on a transaxial MR image, and the right leg-dominant neurological deficit had rapidly progressed. For diagnosis and prevention of neurological deficits, laminectomy between T12 and L1 and tumor resection were performed. The amplitude of intraoperative neurologic monitoring (motor-evoked potentials: MEPs) in the right quadriceps, tibialis anterior, gastrocnemius muscles and sphincter dropped during tumor detachment, and gross total resection was difficult due to severe adhesion to the cauda equina and epiconus.

Microscopically, the tumor consisted of dense sheets of small round cells based on hematoxylin-eosin staining. Immunohistochemically, most tumor cells showed intense and diffuse staining for CD99, ERG and FLI1, and were negative for GFAP, EMA, AE1/AE3, S-100, chromogranin A, and CD57 ([Fig. 3](#f3-ol-0-0-11786){ref-type="fig"}). A nucleotide sequence analysis of the reverse transcription-polymerase chain reaction (RT-PCR) products confirmed that the gene fusion was formed between exon 7 of the EWSR1 gene and exon 5 of the FLI1 gene ([Fig. 4](#f4-ol-0-0-11786){ref-type="fig"}). The lesion was diagnosed as primary intradural Ewing sarcoma at the cauda equina with meningeal seeding.

Chemotherapy (8 cycles of vincristine, doxorubicin and cyclophosphamide (VDC) alternating with ifosfamide and etoposide (IE)) following radiotherapy (total dose of 45 Gy in 25 fractions for the whole spinal lesion excluding the brain) were performed after diagnosis. For Ewing sarcoma, we usually administer vincristine (1.5 mg/m^2^ on day 1), doxorubicin (37.5 mg/m^2^ on days 1 and 2), and cyclophosphamide (1200 mg/m^2^ on day 1) (VDC) alternating with ifosfamide (1.8 g/m^2^ on days 1--5) and etoposide (100 mg/m^2^ on days 1--5) (IE) every 3 weeks. The first course of VDC and second course of IE were administered as full doses. However, we reduced the dosage to 75% and delayed the start of chemotherapy for 1 week in the 3rd to 6th courses due to severe myelosuppression, and we reduced the dosages to 50% of standard chemotherapy in the 7th and 8th courses. Neurological symptoms improved with tumor shrinkage after radiation and chemotherapy; however, multiple brain metastases presenting with symptoms of double vision and hoarseness were found at 10 months after diagnosis ([Fig. 5](#f5-ol-0-0-11786){ref-type="fig"}). Whole-brain irradiation and chemotherapy with another regimen were administered, but the patient died of diffusely disseminated disease limited to the central nervous system, without evidence of distant metastases, at 16 months after the initial diagnosis.

### Histopathology

Histopathological examination was performed on resected specimen fixed 10% formalin for 24 hours at room temperature. Paraffin-embedded sections cut by 4 µm thickness were performed hematoxylin and eosin (H&E) and following immunohistological staining. For immunohistological examination, we used CD99 antibody (cat. no. M3601, DAKO) (1:300 dilution), FLI1 antibody (cat. no. ab15289, abcam) (1:50 dilution) and ERG antibody (cat. no. 41811, Nichirei). For CD99 immunostaining, we didnt perform antigen activation after deparaffinization. For FLI1 immunostaining, we performed antigen activation at 95°C for 20 minutes at pH 6.0 using citrate buffer. For ERG immunostaining, we performed antigen activation at 95°C for 20 minutes at pH 9.0 using TE buffer. We adopted the protocol by using the BONDIII Fully Automated IHC and ISH Stainer (Leica Microsysems, Japan) for all immunohistological staining. Slides were observed under a light microscope.

### RT-PCR and sequencing analyses

Total RNA (53 ng/µl) was extracted from FFPE sections using ISOGEN (Nippon Gene), according to the manufacturers instructions. For specific amplification of the putative EWSR1-FLI1 junction regions, we performed a two-step PCR reaction. The sequences of first primers are EWSR1(ex6) forward, GAGACTAGTCAACCTCAATCTAGC and FLI1(ex6) reverse, AAGCTCCTCTTCTGACTGTG, EWSR1(ex7s) forward CCCACTAGTTACCCACCCCAAA and FLI1(ex8) reverse, GCCCAGGATCTGATACGGAT. The first PCR products were used as template for subsequent PCR reaction using the following nest primers; EWSR1(ex7s) forward, CCCACTAGTTACCCACCCCAAA and FLI1(ex5) reverse, TCGGTGTGGGAGGTTGTATT and FLI1(ex7) reverse, TGATCGTTTGTGCCCCTCCA. The first and nested PCR were performed with the following cycling conditions: 94°C for 3 min, 40 cycles of 94°C, 60°C, and 72°C for 1 min, 72°C for 10 min. ABI PRIZM BigDye Terminator Cycle Sequencing Ready Reaction kits (PE Biosystems) was used for direct sequencing of the nested PCR products. EWSR1-FLI1 fusion gene analysis was performed using ABI PRISM 310 Genetic Analyzer (PE Biosystems). Sequencing reaction products were electrophoresed on 2% agarose gels and stained with ethidium bromide.

### Statistical analysis

The statistical analysis was conducted using SPSS software (v24.0, SPSS). The Kaplan-Meier method was used for calculation of survival. Overall survival (OS) was defined as the time from diagnosis until the most recent follow-up or death of any cause. Progression-free survival was defined as the time from diagnosis until disease progression, death of any cause, or most recent follow-up.

Discussion
==========

We present an extremely rare case of primary intradural extramedurally Ewing sarcoma (IEES). Clinical information for 30 cases of primary IEES reported from 1997 to 2019 is summarized in [Table I](#tI-ol-0-0-11786){ref-type="table"} ([@b6-ol-0-0-11786]--[@b30-ol-0-0-11786]). Of the 30 patients, 18 were male (60%) and 12 were female (40%). The median age at diagnosis was 31 years. The lumbar-sacral region was the most common location (n=20, 66.7%), and multiple lesions viewed as meningeal dissemination were found in 8 patients (26.7%) at diagnosis. The most common chief symptom was pain (n=25, 83.3%). Motor disturbance of a lower or upper limb occurred in 15 patients (50.0%), and bladder and rectal disturbance were present in 8 patients (26.7%).

Ewing sarcoma is categorized as a small round cell sarcoma with pathognomonic molecular findings and varying degrees of neuroectodermal differentiation by immunohistochemistry. Classic Ewing sarcoma lacks neural differentiation and typically has only characteristic diffuse membranous CD99 (encoded by the MIC gene) positivity ([@b31-ol-0-0-11786]). Almost all cases in [Table I](#tI-ol-0-0-11786){ref-type="table"} (n=28, 93.3%) showed CD99 or MIC2 positivity. Ewing sarcoma has a specific translocation involving the EWSR1 gene on chromosome 22, which produces an EWSR1-FLI1 fusion gene transcript and oncoprotein. RT-PCR or fluorescence in situ hybridization (FISH) can be used to detect the fusion gene, and this was detected in 16 of the reported primary IEES cases. The 1- and 5-year OS rates were 79.8% and 26.6%, and the 1-, 2- and 5-year progression free survival rates were 61.0%, 52.3% and 10.9% ([Fig. 6](#f6-ol-0-0-11786){ref-type="fig"}). Although the Kaplan-Meier survival analysis has certain limitation because the patients in [Table I](#tI-ol-0-0-11786){ref-type="table"} had a short duration of follow-up, these results suggest that IEES has a poorer prognosis than conventional localized Ewing sarcoma, which has a 5-year OS of 65--75%. The prognosis of IEES was the same as that of conventional Ewing sarcoma with metastases ([@b4-ol-0-0-11786]).

In general, patients with Ewing sarcoma receive neoadjuvant chemotherapy upon diagnosis of Ewing sarcoma by biopsy. However, spinal tumors are usually diagnosed after resection. All patients in [Table I](#tI-ol-0-0-11786){ref-type="table"} also received adjuvant chemotherapy after diagnosis. In the current case, multiagent chemotherapy was given, including VDC alternating with IE, as described above. However, we had to reduce the dosage and delay the start of chemotherapy for 1 week after the 3rd course because of severe myelosuppression. Zhang *et al* ([@b32-ol-0-0-11786]), suggested that adults with Ewing sarcoma should be treated with adequate cycles of intensive chemotherapy at appropriate intervals. Therefore, it is possible that the effect of chemotherapy was not sufficient in our case.

Ewing sarcoma is radiosensitive ([@b33-ol-0-0-11786]), and in our case we used whole spine radiotherapy without whole brain irradiation. Chihak *et al* ([@b26-ol-0-0-11786]), suggested that craniospinal radiotherapy, rather than focal radiotherapy, is critical for preventing distant metastasis, and skip metastases of intradural Ewing sarcoma to distant sites have been reported ([@b11-ol-0-0-11786],[@b20-ol-0-0-11786],[@b26-ol-0-0-11786]). The patient in our case had a 2-year-old baby, and she refused craniospinal radiotherapy because she was afraid of late cerebral dysfunction. The outcome in this case suggests that craniospinal radiotherapy might be more effective for local control than whole spine radiotherapy.

In conclusion, IEES is an extremely rare malignant tumor that requires multimodal therapy with surgery, craniospinal radiotherapy and systematic chemotherapy. The poorer prognosis of primary IEES compared to that of conventional Ewing sarcoma of bone suggests that new agents and treatment strategies are needed.
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![Sagittal and axial (T12-L1 and L4-5) thoracolumbar magnetic resonance images at the first visit and on admission (3 weeks after the first visit). Growth and increased numbers of semi-oval shaped lesions (isointense signal on T1-weighted, inhomogeneous hyperintense signal on T2-weighted and diffuse gadolinium-enhanced images) occurred within this period.](ol-20-03-2347-g00){#f1-ol-0-0-11786}

![Gadolinium-contrast sagittal T1-weighted images of the (A) cervical and (B) thoracic spinal cord revealed meningeal seeding at C5-6 and T3-4 (arrows). (C) Whole-body PET was negative for disease other than that at the thoracolumbar level. (D) Multiple nodules were positive at the lumbar level in fluorodeoxyglucose-PET. PET, positron emission tomography.](ol-20-03-2347-g01){#f2-ol-0-0-11786}

![Photomicrographs of resected samples. (A) Low-power and (B) high-power images of haematoxylin and eosin staining. Immunohistochemical findings revealed positive staining for (C) CD99, (D) Fli-1 proto-oncogene, ETS transcription factor and (E) ETS transcription factor ERG. Scale bars, 200 µm (A), 20 µm (B) and 50 µm (C-E).](ol-20-03-2347-g02){#f3-ol-0-0-11786}

![Partial nucleotide sequences containing junction of the fusion transcripts in the case. A nucleotide sequence analysis of the reverse transcription-PCR products demonstrated that the gene fusion was formed between exon 7 of the EWSR1 gene and exon 5 of the FLI1 gene. FLI1, Fli-1 proto-oncogene, ETS transcription factor; EWSR1, EWS RNA binding protein 1.](ol-20-03-2347-g03){#f4-ol-0-0-11786}

![Sagittal thoracolumbar MRI revealing tumor shrinkage (A) after radiotherapy (1.5 months after diagnosis) and (B) chemotherapy (9 months after diagnosis). (C) Axial brain MRI revealing multiple brain metastases at 10 months after diagnosis.](ol-20-03-2347-g04){#f5-ol-0-0-11786}

![Kaplan-Meier curves for progression-free survival and overall survival. The 1- and 5-year overall survival rates were 79.8 and 26.6%, respectively. The 1-, 2- and 5-year progression-free survival rates were 61.0, 52.3 and 10.9%, respectively.](ol-20-03-2347-g05){#f6-ol-0-0-11786}

###### 

Summary of reported cases of primary intradural extramedurally Ewing sarcoma.

  Case   Age, years   Sex   Location     IHC (+)                                            IHC (−)                                              EWS-FLI1   Surgery   Chemotherapy regimen            Radiation area   PFS, months   Recurrence   OS, months   Outcome    Refs.
  ------ ------------ ----- ------------ -------------------------------------------------- ---------------------------------------------------- ---------- --------- ------------------------------- ---------------- ------------- ------------ ------------ ---------- -----------------------
  1      14           M     Th12-L2      NSE, synaptophysin, S-100                          GFAP, Desimin, actin                                 \+         GTR       NA                              NA               3M            --           3M           alive      ([@b6-ol-0-0-11786])
  2      52           M     L2-5         CD99, synaptophysin, vimentin                      EMA, LCA lympho marker                               NA         GTR       NA                              craniospinal     12M           --           12M          CDF 1M     ([@b7-ol-0-0-11786])
  3      11           F     C7-T1        CD99, NSE (weakly)                                 CD20, CD45, CD3, Synaptophysin                       NA         STR       NA                              NA               NA            NA           NA           NA         ([@b8-ol-0-0-11786])
  4      31           F     L1-S2        CD99, NSE, synaptophysin, vimentin                 LCA, desmin, GFAP                                    NA         STR       VCR, CCNU, CDDP                 focal            2M            \+           4M           DOD 4M     ([@b9-ol-0-0-11786])
  5      32           M     L2-4         CD99, vimentin                                     NA                                                   \+         STR       Act-D+VDC/IE                    focal            8M            \+           12M          DOD 12M    ([@b10-ol-0-0-11786])
  6      26           M     T11-S2       MIC2                                               LCA                                                  NA         GTR       VAC, ICE                        focal            2M            \+           8M           AWD 8M     ([@b11-ol-0-0-11786])
  7      32           F     C3-C5        CD99, Vimentin                                     NA                                                   NA         STR       IE                              focal            12M           --           12M          CDF 12M    ([@b12-ol-0-0-11786])
  8      10           M     L4-S2        CD99, synaptophysin                                S100, CAM5.2                                         NA         STR       VDC/IE                          focal            12M           --           12M          CDF 12M    ([@b13-ol-0-0-11786])
  9      10           M     C2-3         CD99, vimentin                                     GFAP, NSE, S-100, LCA, lymphoid markers              NA         GTR       --                              --               1M            \+           1M           DOD 1M     ([@b14-ol-0-0-11786])
  10     40           F     T11-L4       Fli1                                               NA                                                   \+         STR       DXR, holoxan                    focal            6M            --           6M           CDF 6M     ([@b15-ol-0-0-11786])
  11     8            M     L2-4         CD99, NSE                                          Syn, CgA, L26, CD3, GFAP                             NA         \+        NA                              NA               NA            --           NA           alive      ([@b16-ol-0-0-11786])
  12     25           M     L2-3         CD99, NSE, S-100                                   L26, UCHI, CD3, CD30, Syn, CK                        NA         \+        NA                              NA               6M            \+           6M           AWD 6M     ([@b16-ol-0-0-11786])
  13     56           F     L1           CD99, s-100, synaptophysin, nurofilament protein   GFAP, EMA, CD20, CD3, keratin, chromogranin, HMB45   \+         GTR       VDC/IE                          NA               NA            NA           NA           CDF        ([@b17-ol-0-0-11786])
  14     55           M     L4-S2        CD99, cavelolin,                                   CD45, EMA, GFAP chromogranin                         \+         GTR       VIDE                            focal            13M           --           13M          CDF 13M    ([@b18-ol-0-0-11786])
  15     25           F     L2-3         CD99, caveolin                                     CD45, CkAE1-AE3, GFAP, chromogranin, p53             \+         GTR       --                              --               14M           \+           14M          alive      ([@b18-ol-0-0-11786])
  16     28           F     L5-S1        S100, Synaptophysin, CD99                          EMA, GFAP, CD20                                      \+         GTR       VDC/IE                          focal            72M           --           72M          CDF 72M    ([@b19-ol-0-0-11786])
  17     44           F     T6-7, L1-2   CD99                                               NA                                                   NA         GTR       VDC/IE                          focal            31M           \+           31M          AWD 31M    ([@b20-ol-0-0-11786])
  18     39           F     C4-6         CD99                                               NA                                                   NA         GTR       VCR, THR, CTX                   focal            36M           \+           36M          alive      ([@b21-ol-0-0-11786])
  19     44           F     L1-S3        CD99, vimentin,                                    NSE, Sinaptophysin, GFAP, S-100, LCA, etc.           NA         GTR       VDC/IE                          focal            6M            --           6M           CDF 6M     ([@b22-ol-0-0-11786])
  20     14           M     L2-S1        CD99                                               CD34, CD 20, S100, NSE, GFAP, Desmin, myogenin       NA         STR       VDC                             focal            NA            NA           12M          CDF 12 M   ([@b23-ol-0-0-11786])
  21     29           M     C7           MIC2, vimentin, cytkeratin, synaptophysin          NA                                                   \+         GTR       VCR, IFO, DXR, VP-16            --               1M            \+           NA           NED 18M    ([@b24-ol-0-0-11786])
  22     5            M     T4-T7        CD99, FLI-1, NSE,                                  Desmin, Myogenin, TdT, CKHMW synaptophysin           NA         STR       NA                              NA               NA            NA           NA           NA         ([@b25-ol-0-0-11786])
  23     50           M     T10-L1       MIC2(CD99), CD56 AE1/AE3                           CD45, S100, GFAP                                     \+         GTR       VDC/IE                          focal            48M           \+           60M          DOD 60M    ([@b26-ol-0-0-11786])
  24     60           M     L2-3         MIC2, CAM5.2, synaptophysin, vimentin              NA                                                   \+         partial   IE/AI                           focal            11M           \+           48M          DOD 48M    ([@b26-ol-0-0-11786])
  25     25           M     C4-7         CD99                                               Actin, MYOD1, chromogranin, synaptophysin            \+         STR       VDC/IE                          focal            NA            \+           20M          NED 20M    ([@b26-ol-0-0-11786])
  26     34           M     L4-5/S1-     CD99, EMA, synaptophysin                           NA                                                   \+         biopsy    VDC/IE                          craniospinal     3M            --           3M           CDF 3M     ([@b26-ol-0-0-11786])
  27     14           F     L2-3         CD99, Fli1                                         EMA, S100, CD20 synaptophysin                        \+         STR       VDC/IE                          focal            24M           --           24M          CDF 24M    ([@b27-ol-0-0-11786])
  28     31           M     L2-L3, L5    CD99                                               GFAP, EMA, cytokeratin, AE1/AE3, S-100               \+         partial   CPA,VCR, ADR, Act-D,IFO,VP-16   --               24M           \+           42M          alive      ([@b28-ol-0-0-11786])
  29     61           M     L1-3         AE1/AE3, CD99, synaptophysin                       GFAP, CD45                                           \+         GTR       VDC/IE                          focal            NA            NA           NA           alive      ([@b29-ol-0-0-11786])
  30     34           F     C4-T3        CD99, CD56                                         Lymphoid, EMA, GFAP, Chromogranin                    \+         partial   --                              craniospinal     9M            \+           11M          DOD 11M    ([@b30-ol-0-0-11786])

NA, not available; AWD, alive with disease; CDF, continuous disease free; NED, no evidence of disease; DOD, dead of disease; GTR, gross total resection; STR, subtotal resection; VCR, Vincristine; CDDP, cisplatin; DXR, doxorubicin; IFO, ifosfamide; CPA, cyclophosphamide; VP-16, etoposide; Act-D, actinomycin D; VDC, VCR+DXR+CPA; IE, IFO+VP-16; IHC, immunohistochemistry; M, male; F, female; PFS, progression-free survival; OS, overall survival.
